The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Fully human therapeutic monoclonal antibodies.
Abstract
Monoclonal antibody (mAb) therapy has been facilitated by a number of technologic advances over the past 30 years. Whereas hybridoma development of murine mAbs was requisite for the development of mAbs as drugs, the inherent immunogenicity of rodent sequences in humans has presented obstacles to the clinical application of mAbs. Sensitization to mAb therapeutics poses significant risk to the patient and may blunt the efficacy of these therapies. The advent of chimeric antibodies lessened but did not eliminate the rodent content of mAbs; thus, immunogenicity remained a concern. Further elimination of rodent sequences enabled the production of humanized mAbs, followed by current technology using phage display and, finally, transgenic mice technology, which allows for the generation of fully human therapeutic mAbs. The reduced immunogenicity of this new generation of mAbs is expected to enhance efficacy, safety, and ease of use. In addition to providing replacements for existing mAb drugs, new technologies have greatly facilitated the optimization and modification of mAbs, opening numerous therapeutic avenues.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Denosumab and numerous other fully human therapeutic antibodies have been made in transgenic mice, wherein their murine Ig genes have been deleted and replaced with human orthologs (431, 432).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [431]
In the citing paper
“Another potential advantage of a fully human anti-RANKL antibody is the low potential for immune responses (431), a theoretical attribute that has been borne out in clinical trials with denosumab.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [431]
Citations
Cites
Continuous cultures of fused cells secreting antibody of predefined specificity
Köhler, G., & Milstein, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,200
Smith, G. P. (1985) · Science · doi:10.1126/science.4001944 · Cited by 4,143
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Phage antibodies: filamentous phage displaying antibody variable domains
McCafferty, J., Griffiths, A. D., Winter, G. P., & Chiswell, D. J. (1990) · Nature · doi:10.1038/348552a0 · Cited by 2,427
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
Baert, F., Noman, M., Vermeire, S., Assche, G. V., Haens, G. D., Carbonez, A., & Rutgeerts, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020888 · Cited by 2,012
Huston, J. S., Levinson, D., Mudgett-Hunter, M., Tai, M. S., Novotný, J., Margolies, M. N., Ridge, R. J., Bruccoleri, R. E., Haber, E., & Crea, R. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.16.5879 · Cited by 1,610
Marks, J. D., Hoogenboom, H. R., Bonnert, T. P., McCafferty, J., Griffiths, A. D., & Winter, G. P. (1991) · Journal of Molecular Biology · doi:10.1016/0022-2836(91)90498-u · Cited by 1,605
Reshaping human antibodies for therapy
Riechmann, L., Clark, M., Waldmann, H., & Winter, G. P. (1988) · Nature · doi:10.1038/332323a0 · Cited by 1,565
Single-Chain Antigen-Binding Proteins
Bird, R. E., Hardman, K. D., Jacobson, J. W., Johnson, S., Kaufman, B. M., Lee, S., Lee, T. T., Pope, S. H., Riordan, G. S., & Whitlow, M. D. (1988) · Science · doi:10.1126/science.3140379 · Cited by 1,522
McCune, J. M., Namikawa, R., Kaneshima, H., Shultz, L. D., Lieberman, M., & Weissman, I. L. (1988) · Science · doi:10.1126/science.2971269 · Cited by 1,404
Research works printed but not linked: 5
- Skamene, 1971, Clin Exp Immunol, 8, 195
- Hale, 1983, Mol Biol Med, 1, 321
- Yokota, 1993, Cancer Res, 53, 3776
- Adams, 2001, Cancer Res, 61, 4750
- Milenic, 1991, Cancer Res, 51, 6363
Cited by
Sorted by citations
Items 101–164 of 164
Arocho, R., de Paredes, M. G., Maurel, J., Lema, M., Hart, W. M., & Rubio‐Terres, C. (2009) · PharmacoEconomics Spanish Research Articles · doi:10.1007/bf03320852 · Cited by 7
Panitumumab in the Treatment of Metastatic Colorectal Cancer1
Hoy, S. M., & Wagstaff, A. J. (2007) · BioDrugs · doi:10.2165/00063030-200721020-00011 · Cited by 7
Automation of Selection and Engineering
Konthur, Z. (2007) · Wiley eBooks · doi:10.1002/9783527619740.ch17 · Cited by 7
Beyond bevacizumab: a review of targeted agents in metastatic small bowel adenocarcinoma
Sacdalan, D. B., Mendoza, M. J., Vergara, J. P., Catedral, L. I. G., Ting, F. I. L., Leones, L. M. B., Berba, C. M., & Sacdalan, D. L. (2020) · Medical Oncology · doi:10.1007/s12032-020-01432-3 · Cited by 6
Infusion Reactions Triggered by Monoclonal Antibodies Treating Solid Tumors
Carney, P. H., & Ollom, C. L. (2008) · Journal of Infusion Nursing · doi:10.1097/01.nan.0000313654.57786.bb · Cited by 6
Liew, P. X., Ge, F., Gullo, C. A., Teoh, G. K. H., & Hwang, W. Y. K. (2009) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.v38n7p621 · Cited by 6
Antibodies and Fusion Proteins
Kirk, A. D. (2008) · Elsevier eBooks · doi:10.1016/b978-1-4160-3343-1.50024-4 · Cited by 6
The problems of THE immunogenicity of biologicals: theory and practice
Karateyev, D. E. (2009) · Modern Rheumatology Journal · doi:10.14412/1996-7012-2009-527 · Cited by 6
Immunogenicity of biologic agents: A new concern for the practicing rheumatologist?
Haraoui, B. P., Pelletier, J., & Martel‐Pelletier, J. (2007) · Current Rheumatology Reports · doi:10.1007/s11926-007-0042-x · Cited by 6
Does one model fit all mAbs? An evaluation of population pharmacokinetic models
van den Berg, S. P. H., Adolfsen, P. E. A., Dorlo, T. P. C., & Rispens, T. (2025) · mAbs · doi:10.1080/19420862.2025.2512217 · Cited by 5
Therapeutic Antibodies and Immunologic Conjugates
Cheung, N. V. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00032-1 · Cited by 5
Sofla, F. J. I., Rahbarizadeh, F., Ahmadvand, D., Nomani, A., & Vernet, E. (2018) · Journal of Bioactive and Compatible Polymers · doi:10.1177/0883911518813677 · Cited by 5
Cowden, J., & Parker, S. K. (2006) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000223443.80696.5b · Cited by 5
Anti-inflammatory Drugs and the Gastrointestinal Tract
Merćep, M. (2024) · Clinical gastroenterology · doi:10.1007/978-3-031-69800-2_9 · Cited by 4
How real is the long-lasting effect of tumor necrosis factor α inhibitors? Focus on immunogenicity
Karateev, D. E. (2014) · Modern Rheumatology Journal · doi:10.14412/1996-7012-2014-2-35-40 · Cited by 4
Monoclonal Antibodies: From Structure to Therapeutic Application
Deng, R., Li, J., Boswell, C. A., Joshi, A., & Li, C. (2024) · Springer eBooks · doi:10.1007/978-3-031-30023-3_8 · Cited by 6
Radiolabeled Antibodies for Cancer Radioimmunotherapy
Rousseau, J., Lau, J., & Bénard, F. (2021) · Springer eBooks · doi:10.1007/978-3-030-81261-4_14 · Cited by 4
Monoclonal antibodies: Pharmacological relevance
Kaur, J., Badyal, D. K., & Khosla, P. (2007) · Indian Journal of Pharmacology · doi:10.4103/0253-7613.30755 · Cited by 4
Role of Antibodies in Cancer Treatment (An Overview)
Albrecht, H. (2009) · Springer eBooks · doi:10.1007/978-90-481-3186-0_10 · Cited by 4
Hust, M., Frenzel, A., Tomszak, F., Kügler, J., & Dübel, S. (2014) · doi:10.1002/9783527682423.ch3 · Cited by 4
Nomenklatur und Einteilung von Biologicals
Eichbaum, C., & Haefeli, W. E. (2011) · Therapeutische Umschau · doi:10.1024/0040-5930/a000219 · Cited by 3
Impact of Trisulfide on the Structure and Function of Different Antibody Constructs
Sun, Z., Huang, M., Sokolowska, I., Cao, R., Chang, K., Hu, P., & Mo, J. (2023) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2023.08.010 · Cited by 3
Essay: Monoclonal antibodies—designer medical missiles
Stone, M. J. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69926-1 · Cited by 3
Antibody engineering: Molecular constructor on the basis of barnase-barstar module
Deyev, S. M., & Lebedenko, E. N. (2009) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162009060041 · Cited by 3
Marshall, D., Mitchell, D. A., Graner, M. W., & Bigner, D. D. (2012) · Handbook of clinical neurology · doi:10.1016/b978-0-444-52138-5.00020-7 · Cited by 3
Monoclonal Antibodies: From Structure to Therapeutic Application
Deng, R., Boswell, C. A., Putnam, W. S., Tang, M. T., Garg, A., Li, C., Chung, S., & Girish, S. (2019) · Springer eBooks · doi:10.1007/978-3-030-00710-2_8 · Cited by 3
Sirohi, B., & Powles, R. (2007) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705865 · Cited by 3
Chemical and Genetic Modification
Farys, M., Ginn, C., Badescu, G. O., Peciak, K., Pawlisz, E., Khalili, H., & Brocchini, S. (2013) · Wiley eBooks · doi:10.1002/9780470571224.pse508 · Cited by 3
Antilymphocyte Globulin, Monoclonal Antibodies, and Fusion Proteins
Kirk, A. D. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-4096-3.00020-9 · Cited by 2
Li, F., & Ji, Q. C. (2011) · doi:10.1002/9780470929278.ch19 · Cited by 2
Lim, E. C. H., Oh, V. M. S., Ong, B. K. C., Chow, A. W. L., & Seet, R. C. S. (2006) · Medical Hypotheses · doi:10.1016/j.mehy.2006.03.014 · Cited by 2
Biotechnological advances in monoclonal antibody therapy: the RANK ligand inhibitor antibody
Kiss, E. V., Kuluncsics, Z., Kiss, Z., & Poór, G. (2010) · Orvosi Hetilap · doi:10.1556/oh.2010.29010 · Cited by 1
Recent advances in antibody technique(1):Humanized antibody technique
Hong, W. (2012) · Journal of Jinan University · Cited by 1
Inclusion of Human Chorionic Gonadotropin in the Family of Therapeutic Glycoproteins
Rao, C. V. (2017) · Women s Health - Open Journal · doi:10.17140/whoj-3-119 · Cited by 1
Antilymphocyte Globulin, Monoclonal Antibodies, and Fusion Proteins
Chambers, E. T., & Kirk, A. D. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-53186-3.00019-x · Cited by 1
Dhar, S. K., & Das, M. (2018) · Journal of the Indian Institute of Science · doi:10.1007/s41745-018-0061-9 · Cited by 1
Preclinical Safety Evaluation of Monoclonal Antibodies
Treacy, G., & Martin, P. L. (2010) · Pharmaceutical Sciences Encyclopedia · doi:10.1002/9780470571224.pse185 · Cited by 1
Expanding horizons in metastatic prostate cancer treatment
Fizazi, K. S., & Goessl, C. D. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.67-c1 · Cited by 1
Yu, G., & Ni, J. (2011) · Wiley eBooks · doi:10.1002/9780470571224.pse431
Munar, M. A., Pantoja, J. A., Santacruz, J. C., Villate, A. M., Bastidas, A., & Giraldo‐Cadavid, L. F. (2012) · Revista Med · doi:10.18359/rmed.1203
Ciblage thérapeutique des tumeurs osseuses primitives par transfert de gène
Lamoureux, F. (2008) · OpenGrey (Institut de l'Information Scientifique et Technique)
Antibodies for Nuclear Medicine Therapy
Goldenberg, D. M., & Sharkey, R. M. (2012) · Medical radiology · doi:10.1007/174_2012_670
Proteins: Hormones, Enzymes, and Monoclonal Antibodies—Background
Materi, W., Gombos, Z., & Wishart, D. S. (2010) · Pharmaceutical Sciences Encyclopedia · doi:10.1002/9780470571224.pse312
Research Advance in Single-Domain Antibody
刘, 晟. (2015) · QianRen Biology · doi:10.12677/qrb.2015.23004
Construction and screening of human phage display antibody library against lung adenocarcinoma
Luo, Y., Pang, H., Li, S., Cao, H., & Peng, Z. (2010) · Academic Journal of Second Military Medical University · doi:10.3724/sp.j.1008.2009.00087
Anticorpos monoclonais no tratamento da asma Monoclonal antibodies in asthma treatment
Agondi, R. C., Aun, M. V., Bisaccioni, C., Kalil, J. E., Machado, A. D. S., França, A. T., da Costa, E. M. D. S. A. Z. A. C., Sano, F., Wandalsen, G. F., Rizzo, J. Â., et al. (2012)
Evolução in vitro de anticorpos anti-CD3 pela seleção de cadeias leve (VL) humanas por phage display
Oliveira, Y. S. (2009) · Americanae (AECID Library)
Immune Based Therapies for Inflammatory Bowel Disease
Sinh, P., Fiocchi, C., & Achkar, J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803302-9.00003-8
Generation of Human Antibodies Against a Specific Peptide: a Novel Strategy Based on Human Cells
Toloudi, M., Papadimitriou, M., Pantopikou, K., & Papasotiriou, I. (2016) · Anticancer Research · doi:10.21873/anticanres.11011
ADCC Enhancement Technologies for Next‐Generation Therapeutic Antibodies
Liu, C., & Yan, S. (2016) · doi:10.1002/9781118940648.ch20
Biothérapies et anticorps monoclonaux
Séror, R., & Pagnoux, C. (2010) · Elsevier eBooks · doi:10.1016/b978-2-294-71107-7.50059-7
Immunotherapy for cancer of the oral cavity and oropharynx. The use of monoclonal antibodies
Hirna, H. A., Kostyshyn, I. D., Rozhko, M. M., & Levandovskyi, R. A. (2020) · Bukovinian Medical Herald · doi:10.24061/2413-0737.xxiv.2.94.2020.61
Ілащук, Т. О., & Горевич, С. С. (2020) · Bukovinian Medical Herald · doi:10.24061/2413-0737.xxiv.2.94.2020.62
Therapeutic Antibodies and Immunologic Conjugates
Cheung, N. V. (2008) · Elsevier eBooks · doi:10.1016/b978-0-443-06694-8.50038-5
Production and Therapeutic Applications of Monoclonal Antibodies in Cancer and Other Diseases
Shahi, A., Patel, G. K., Kumar, S., Singh, M., Varshney, A., & Ghoshal, U. C. (2024) · Wiley eBooks · doi:10.1002/9783527844340.ch26
Advances in Population Pharmacokinetics of Monoclonal Antibody Drugs
Mu, S., Zhang, X., Jin, J., Tong, Y., Sun, J., Wang, R., & Li, W. (2025) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000001374
Biomarkers for drug development in kidney transplantation
Pattanaik, S., & van Gelder, T. (2025) · Elsevier eBooks · doi:10.1016/b978-0-12-824069-4.00016-1
Les claudines dans le cancer colorectal : ciblage thérapeutique de la claudine-1
Cherradi, S. (2018) · theses.fr (ABES) · doi:10.70675/9002c99ez8e92z4779z9e11zb6d83f9bf057
Ji, Y., Calonder, C., Kirsilä, T., Burciu, A., Laurent, N., Hua, E., Severin, T. M., Patekar, M., & Woessner, R. (2026) · Clinical and Translational Science · doi:10.1111/cts.70661
Bibeau, F., & Boissière‐Michot, F. (2014) · ONCOLOGIE · doi:10.1007/s10269-014-2377-z
Metadata
- Authors
- Weiner, L. M.
- Affiliations
- Fox Chase Cancer Center (US)
- Corresponding author
- Weiner, Louis M
- ORCID
- Weiner, Louis M
- Venue
- Journal of Immunotherapy
- Published
- 2006-01
- Volume
- 29
- Issue
- 1
- Pages
- 1-9
- ISSN
- 1524-9557 (ISSN-L)
- OpenAlex
- W1971456299
- Cited by
- 164
- References
- 36
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 3 · 2023: 2 · 2022: 2 · 2021: 4 · 2020: 5 · 2019: 7 · 2018: 4 · 2017: 1 · 2016: 5 · 2015: 9 · 2014: 8 · 2013: 9 · 2012: 17
- FWCI
- 2.09
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Immunotherapy (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA 50633, CA06926, R01CA050633)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
- Keywords
- monoclonal antibodies, fully human antibodies, immunogenicity, chimeric antibodies, humanized monoclonal antibody, transgenic mice, phage display, hybridoma technology, antibody engineering, therapeutic antibodies
- MeSH terms
- Animals, Antibodies, Monoclonal, Genetic Engineering, Humans, Mice, Transgenic, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
